Literature DB >> 19614742

The use of synthetic linear tetrapyrroles to probe the verdin sites of human biliverdin-IXalpha reductase and human biliverdin-IXbeta reductase.

Edward M Franklin1, Seamus Browne, Anne M Horan, Katsuhiko Inomata, Mostafa A S Hammam, Hideki Kinoshita, Tilman Lamparter, Georgia Golfis, Timothy J Mantle.   

Abstract

Many vertebrate species express two enzymes that are capable of catalysing the reduction of various isomers of biliverdin. Biliverdin-IXalpha reductase (BVR-A) is most active with its physiological substrate biliverdin-IXalpha, but can also reduce the three other biliverdin isomers IXbeta, IXdelta and IXgamma. Biliverdin-IXbeta reductase (BVR-B) catalyses the reduction of only the IXbeta, IXdelta and IXgamma isomers of biliverdin. Therefore, the activity of BVR-A can be measured using biliverdin-IXalpha as a specific substrate. We now show that the dimethyl esters of biliverdin-IXbeta and biliverdin-IXdelta are substrates for BVR-B, but not for BVR-A. This provides a useful method for specifically assaying the activity of both BVR-A and BVR-B in crude mixtures, using biliverdin-IXalpha for BVR-A and the dimethyl ester of either biliverdin-IXbeta or biliverdin-IXdelta for BVR-B. Human BVR-A has been suggested as a pharmacological target for neonatal jaundice. Because of the absence of a crystal structure with biliverdin bound to BVR-A, we have investigated indirect ways of examining tetrapyrrole binding. In the present study, we report that a number of sterically locked conformers of 18-ethylbiliverdin-IXalpha are substrates for human BVR-A, and discuss the implications for the biliverdin binding site. The oxidation of bilirubin-IXalpha ditaurate to biliverdin-IXalpha ditaurate is also described. We show that biliverdin-IXalpha ditaurate is a substrate for human BVR-A and discuss the possibility of using a competing substrate, which is reduced to a water soluble and excretable rubin, as a prototypic inhibitor of BVR-A.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19614742     DOI: 10.1111/j.1742-4658.2009.07148.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  10 in total

1.  Bliverdin reductase-A improves neurological function in a germinal matrix hemorrhage rat model.

Authors:  Yiting Zhang; Yan Ding; Tai Lu; Yixin Zhang; Ningbo Xu; Lingyan Yu; Devin W McBride; Jerry J Flores; Jiping Tang; John H Zhang
Journal:  Neurobiol Dis       Date:  2017-12-05       Impact factor: 5.996

2.  Heme degradation enzyme biliverdin IXβ reductase is required for stem cell glutamine metabolism.

Authors:  Zongdong Li; Natasha M Nesbitt; Lisa E Malone; Dimitri V Gnatenko; Song Wu; Daifeng Wang; Wei Zhu; Geoffrey D Girnun; Wadie F Bahou
Journal:  Biochem J       Date:  2018-03-29       Impact factor: 3.857

3.  Biliverdin amides reveal roles for propionate side chains in bilin reductase recognition and in holophytochrome assembly and photoconversion.

Authors:  Lixia Shang; Nathan C Rockwell; Shelley S Martin; J Clark Lagarias
Journal:  Biochemistry       Date:  2010-07-27       Impact factor: 3.162

4.  Lack of p53 decreases basal oxidative stress levels in the brain through upregulation of thioredoxin-1, biliverdin reductase-A, manganese superoxide dismutase, and nuclear factor kappa-B.

Authors:  Eugenio Barone; Giovanna Cenini; Rukhsana Sultana; Fabio Di Domenico; Ada Fiorini; Marzia Perluigi; Teresa Noel; Chi Wang; Cesare Mancuso; Daret K St Clair; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2012-02-21       Impact factor: 8.401

5.  Biliverdin reductase--a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment.

Authors:  Eugenio Barone; Fabio Di Domenico; Giovanna Cenini; Rukhsana Sultana; Chiara Cini; Paolo Preziosi; Marzia Perluigi; Cesare Mancuso; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2011-01-15

Review 6.  Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets.

Authors:  Eugenio Barone; Fabio Di Domenico; D Allan Butterfield
Journal:  Biochem Pharmacol       Date:  2013-11-11       Impact factor: 5.858

7.  BLVRB redox mutation defines heme degradation in a metabolic pathway of enhanced thrombopoiesis in humans.

Authors:  Song Wu; Zongdong Li; Dmitri V Gnatenko; Beibei Zhang; Lu Zhao; Lisa E Malone; Nedialka Markova; Timothy J Mantle; Natasha M Nesbitt; Wadie F Bahou
Journal:  Blood       Date:  2016-05-16       Impact factor: 22.113

8.  In silico and crystallographic studies identify key structural features of biliverdin IXβ reductase inhibitors having nanomolar potency.

Authors:  Natasha M Nesbitt; Xiliang Zheng; Zongdong Li; José A Manso; Wan-Yi Yen; Lisa E Malone; Jorge Ripoll-Rozada; Pedro José Barbosa Pereira; Timothy J Mantle; Jin Wang; Wadie F Bahou
Journal:  J Biol Chem       Date:  2018-02-27       Impact factor: 5.157

9.  Divergent erythroid megakaryocyte fates in Blvrb-deficient mice establish non-overlapping cytoprotective functions during stress hematopoiesis.

Authors:  Natasha M Nesbitt; Lisa E Malone; Zhaoyan Liu; Alexander Jares; Dmitri V Gnatenko; Yupo Ma; Wei Zhu; Wadie F Bahou
Journal:  Free Radic Biol Med       Date:  2020-12-24       Impact factor: 7.376

10.  Unprecedented Microbial Conversion of Biliverdin into Bilirubin-10-sulfonate.

Authors:  Ryan G Shiels; Josif Vidimce; Andrew G Pearson; Ben Matthews; Karl-Heinz Wagner; Andrew R Battle; Harry Sakellaris; Andrew C Bulmer
Journal:  Sci Rep       Date:  2019-02-27       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.